Płatkowska-Adamska Bernadetta, Bociek Agnieszka, Kal Magdalena, Zarębska-Michaluk Dorota, Odrobina Dominik
Medical and Health Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland -
Department of Ophthalmology, John Boni Fratres Lodziensis, Łódź, Poland -
Minerva Med. 2024 Dec;115(6):643-650. doi: 10.23736/S0026-4806.24.09379-0. Epub 2024 Oct 11.
Due to safety concerns, patients were hesitant to receive a booster dose of COVID-19 vaccine. In this study, we investigated whether neovascular age-related macular degeneration activity deteriorated after receiving the booster dose of the BNT162b2 vaccine.
Optical coherence tomography (OCT) of the macula, best-corrected visual acuity (BCVA), and slit-lamp examination data were collected from 89 patients. All these individuals were diagnosed with neovascular age-related macular degeneration (AMD) and treated with intravitreal injections of aflibercept or ranibizumab. During the process of treatment, patients received a booster dose of the BNT162b2 vaccine. Time points included two visits before (marked as "-2", "-1") and two visits after (marked as "1", "2") the uptake of the booster dose.
There were significant differences in the average thickness and total volume of the macula during follow-up. Moreover, a decreased average thickness, total volume, total thickness of the macula, subretinal fluid thickness, and subretinal complex thickness was observed between the time points "-2" and "2", but only in the aflibercept group. There were no significant differences in the frequency of occurring intraretinal cysts, subretinal fluid, serous retinal pigment epithelial detachments retinal hemorrhage, subretinal hyperreflective material, complete RPE and outer retinal atrophy, and BCVA before and after the booster dose.
These results demonstrate that the BNT162b2 vaccine booster dose did not deteriorate the course of neovascular AMD.
出于安全考虑，患者对接种新冠病毒疫苗加强针犹豫不决。在本研究中，我们调查了接受BNT162b2疫苗加强针后新生血管性年龄相关性黄斑变性的病情是否恶化。
收集了89例患者的黄斑光学相干断层扫描（OCT）、最佳矫正视力（BCVA）和裂隙灯检查数据。所有这些个体均被诊断为新生血管性年龄相关性黄斑变性（AMD），并接受了玻璃体内注射阿柏西普或雷珠单抗治疗。在治疗过程中，患者接受了BNT162b2疫苗加强针。时间点包括接种加强针前的两次就诊（标记为“-2”，“-1”）和接种后的两次就诊（标记为“1”，“2”）。
随访期间黄斑的平均厚度和总体积存在显著差异。此外，在“-2”和“2”时间点之间观察到黄斑的平均厚度、总体积、黄斑总厚度、视网膜下液厚度和视网膜下复合体厚度有所下降，但仅在阿柏西普组中出现。加强针接种前后视网膜内囊肿、视网膜下液、浆液性视网膜色素上皮脱离、视网膜出血、视网膜下高反射物质、完全视网膜色素上皮和外层视网膜萎缩的发生率以及BCVA均无显著差异。
这些结果表明，BNT162b2疫苗加强针并未使新生血管性AMD的病程恶化。
